SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has SpringWorks Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SWTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SWTX's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: SWTX exceeded the US Biotechs industry which returned 24.5% over the past year.
Return vs Market: SWTX exceeded the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is SpringWorks Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StCan You Imagine How Jubilant SpringWorks Therapeutics' (NASDAQ:SWTX) Shareholders Feel About Its 122% Share Price Gain?
2 months ago | Simply Wall StWe're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
Is SpringWorks Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SWTX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SWTX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SWTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SWTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SWTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SWTX is overvalued based on its PB Ratio (7.7x) compared to the US Biotechs industry average (2.8x).
How is SpringWorks Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SWTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SWTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SWTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SWTX's revenue (56.3% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: SWTX's revenue (56.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SWTX is forecast to be unprofitable in 3 years.
How has SpringWorks Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SWTX is currently unprofitable.
Growing Profit Margin: SWTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SWTX is unprofitable, and losses have increased over the past 5 years at a rate of 43.1% per year.
Accelerating Growth: Unable to compare SWTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SWTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).
Return on Equity
High ROE: SWTX has a negative Return on Equity (-11.23%), as it is currently unprofitable.
How is SpringWorks Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SWTX's short term assets ($481.5M) exceed its short term liabilities ($18.7M).
Long Term Liabilities: SWTX's short term assets ($481.5M) exceed its long term liabilities ($1.2M).
Debt to Equity History and Analysis
Debt Level: SWTX is debt free.
Reducing Debt: SWTX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SWTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SWTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 38.7% each year
What is SpringWorks Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SWTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SWTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SWTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SWTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SWTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Saqib Islam (51 yo)
Mr. Saqib Islam, J.D. serves as Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isl...
CEO Compensation Analysis
Compensation vs Market: Saqib's total compensation ($USD7.74M) is above average for companies of similar size in the US market ($USD5.32M).
Compensation vs Earnings: Saqib's compensation has increased whilst the company is unprofitable.
Experienced Management: SWTX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: SWTX's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
SpringWorks Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: SpringWorks Therapeutics, Inc.
- Ticker: SWTX
- Exchange: NasdaqGS
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.127b
- Shares outstanding: 48.37m
- Website: https://www.springworkstx.com
Number of Employees
- SpringWorks Therapeutics, Inc.
- 100 Washington Boulevard
- United States
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an o...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/03 00:47|
|End of Day Share Price||2021/08/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.